# Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)

Study · id `cardio:ct-nct02831361` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02831361](<https://clinicaltrials.gov/study/NCT02831361>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02831361

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 290 participants.

## Technical summary

Registry record NCT02831361. Randomized; double masking; primary purpose treatment. Start 2016-10-17 (actual); primary completion 2018-02-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 290 participants (enrolled count; ClinicalTrials.gov record NCT02831361, source copy `cardio:ctgov-nct02831361-2018-02-22`, retrieved 2026-10-26)
- Started: 2016-10-17 (actual) (ClinicalTrials.gov record NCT02831361, source copy `cardio:ctgov-nct02831361-2018-02-22`, retrieved 2026-10-26)
- Primary completion: 2018-02-08 (actual) (ClinicalTrials.gov record NCT02831361, source copy `cardio:ctgov-nct02831361-2018-02-22`, retrieved 2026-10-26)
- Completion: 2018-02-08 (actual) (ClinicalTrials.gov record NCT02831361, source copy `cardio:ctgov-nct02831361-2018-02-22`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02831361-2018-02-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Trial to Evaluate the Efficacy and Safety of Gemigliptin Compared With Placebo Added on Insulin Alone or on Insulin in Combination With Metformin in Type 2 DM (ZEUS II Study)
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Gemigliptin
- Intervention (Drug): Gemigliptin placebo
- Intervention (Drug): Metformin
- Intervention (Procedure): Diet/exercise questionnaire
- Lead sponsor: LG Life Sciences
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: LG Life Sciences (`cardio:org-lg-life-sciences`)

## Provenance

Content hash: 7dea750c085b67c5d6bd5a6afe3d9b775005b804409930385f1cb6f664ba2d6d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
